Tag: Immunotherapy
Guselkumab Efficacious for Moderately to Severely Active Crohn Disease in Adults
Both guselkumab regimens superior to placebo
Presurgical Immunotherapy Offers Long-Term Benefit in Melanoma
80 percent of adult patients with stage III/IV resectable melanoma remained event-free at four years from the start of neoadjuvant systemic treatment
Many Ineligible for Clinical Trial Could Benefit From Teclistamab for Multiple Myeloma
89 percent of 509 patients would have been ineligible for MajesTEC-1 trial; estimated median PFS was 5.8 months
Cell Therapy MDR-101 Produces Functional Immune Tolerance in Kidney Transplant Recipients
Fifteen of 20 HLA-matched living donor recipients achieved the primary end point of being immunosuppression-free for more than two years
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
Introduction of immune checkpoint inhibitors linked to widening disparity for those with private insurance versus those without insurance
Adding Pembrolizumab to Standard Care Ups Event-Free Survival in Head, Neck Cancer
Addition of neoadjuvant and adjuvant pembrolizumab to standard care significantly improves event-free survival
FDA Approves Monjuvi for Relapsed, Refractory Follicular Lymphoma
Significantly improved progression-free survival seen with Monjuvi in combination with rituximab and lenalidomide
Mitochondrial Genetics Key to Metastatic Melanoma Immunotherapy Resistance
Patients belonging to haplogroup T exhibit unique nivolumab-resistant baseline peripheral CD8+ T-cell repertoire
Dostarlimab + Chemo Beneficial for Advanced, Recurrent Endometrial Cancer
Longer mean duration of quality-adjusted time without symptoms of disease progression or toxicity of treatment seen with dostarlimab
ASCO: Durvalumab Plus FLOT Beneficial for Resectable Gastric, GE Junction Cancer
Better event-free survival outcomes seen for durvalumab plus FLOT versus FLOT alone in phase 3 randomized trial
